ASCO Issues New Recommendation Cosela (Trilaciclib) in Update to its Treatment Guidelines for Small Cell Lung Cancer
October 20, 2023
On October 11, 2023, the American Society of Clinical Oncology (ASCO) recommended an update to its treatment guidelines for small cell lung cancer (SCLC). Cosela (trilaciclib) has been recommended as a myeloid supportive agent for individuals with extensive-stage SCLC who are receiving treatment with chemotherapy or chemoimmunotherapy.Myelosuppression or bone marrow suppression (when bone marrow does not make enough blood cells or platelets), is a common side effect for individuals receiving chemotherapy and increases the risk of blood disorders such as anemia (low red blood cell count), bleeding, or infection. The updated guidelines offer doctors a new way to manage this potentially harmful side effect of chemotherapy for persons receiving treatment for SCLC.Read the full update to ASCO’s treatment guidelines here.
Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.